Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
Esperion (ESPR) Q1 Earnings and Revenues Beat Estimates
03:47pm, Thursday, 07'th May 2020
Esperion Therapeutics (ESPR) reports encouraging first-quarter results. The company records product revenues for the first time during the quarter.
U.S. RESEARCH ROUNDUP-Ashland Global, Lyft, Solaredge Technologies
03:19pm, Thursday, 07'th May 2020
Wall Street securities analysts on Thursday revised their ratings and
price targets on several U.S.-listed companies, including Ashland Global Holdings, Lyft and
Solaredge Technologies.
HIGH
Esperion Therapeutics Inc (ESPR) Q1 2020 Earnings Call Transcript
01:01pm, Thursday, 07'th May 2020
ESPR earnings call for the period ending March 31, 2020.
Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference
12:00pm, Thursday, 07'th May 2020
Esperion (ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the BofA Securities 2020 Healthcare Conference on Tues
Edited Transcript of ESPR earnings conference call or presentation 6-May-20 8:30pm GMT
11:29am, Thursday, 07'th May 2020
Q1 2020 Esperion Therapeutics Inc Earnings Call
Esperion Therapeutics' (ESPR) CEO Tim Mayleben on Q1 2020 Results - Earnings Call Transcript
04:08am, Thursday, 07'th May 2020
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2020 Earnings Conference Call May 6, 2020 4:30 PM ET Company Participants Alex Schwartz – Head-Investor Relations T
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
10:55pm, Wednesday, 06'th May 2020
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 9.55% and 91.67%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Esperion Therapeutics Q1 EPS $(2.840) Beats $(3.290) Estimate, Sales $1.840M Beat $520.000K Estimate
08:28pm, Wednesday, 06'th May 2020Esperion Reports First Quarter 2020 Financial Results and Provides Company Update
08:05pm, Wednesday, 06'th May 2020
Company Secures Marketing Approvals for NEXLETOL™ and NEXLIZET™ Tablets in the U.S. as well as for NILEMDO™ and NUSTENDI™ Tablets in EuropeNEXLETOL™ (bempedoic acid) Tablets.
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
12:00am, Wednesday, 06'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs May 5)
• Adverum Biotechnologies...
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Esperion to Report First Quarter 2020 Financial Results May 6, 2020
12:00pm, Thursday, 30'th Apr 2020
ANN ARBOR, Mich., April 30, 2020 -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2020 financial results after the close of the U.S. financial markets on.
Weekly Analysts' Ratings Updates for Esperion Therapeutics (ESPR)
07:36am, Thursday, 30'th Apr 2020
Several analysts have recently updated their ratings and price targets for Esperion Therapeutics (NASDAQ: ESPR): 4/21/2020 – Esperion Therapeutics was upgraded by analysts at BidaskClub from a “se
Esperion Therapeutics Inc (NASDAQ:ESPR) Expected to Post Quarterly Sales of $960,000.00
08:00am, Monday, 27'th Apr 2020
Equities research analysts predict that Esperion Therapeutics Inc (NASDAQ:ESPR) will post $960,000.00 in sales for the current quarter, according to Zacks Investment Research. Two analysts have provid
Esperion Therapeutics (NASDAQ:ESPR) Rating Increased to Hold at BidaskClub
06:32am, Saturday, 25'th Apr 2020
BidaskClub upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a sell rating to a hold rating in a report released on Tuesday morning, BidAskClub reports. Several other research firms have als
